Isomorphic Labs, the drug discovery company spun out of Google DeepMind in 2021, raised $2.1 billion in a Series B on May 12, 2026, led by Thrive Capital. It has research deals with Eli Lilly, Novartis and Johnson & Johnson. As of November 13, 2026, we found no Isomorphic study on ClinicalTrials.gov, and press coverage from November 3 said no candidate had entered human trials. The company's stated target is a first clinical trial by the end of 2026, a year later than first said.
Funding Rounds
| Date | Round | Amount | Lead | Other investors |
|---|---|---|---|---|
| 2021 | Founded as an Alphabet company | Not disclosed | Alphabet | |
| March 2025 | First external round | $600M | Thrive Capital | Not listed in our sources |
| May 12, 2026 | Series B | $2.1B | Thrive Capital | Alphabet and GV (existing). MGX, Temasek, CapitalG and the UK Sovereign AI Fund (new) |
The valuation was not disclosed. Reuters said the company did not respond on valuation. The two external rounds add up to $2.7 billion, which is the figure Sacra gives. R&D World put total outside capital at about $2.6 billion. Neither figure includes Alphabet's earlier funding.
The company said the Series B will pay for further work on its drug design engine, known as IsoDDE, for moving its own programmes toward the clinic, and for hiring in AI, engineering, drug design and clinical roles.
Partners and Deal Values
| Partner | Announced | Upfront | Milestones | Scope |
|---|---|---|---|---|
| Eli Lilly | January 2024 | $45M | Up to $1.7B | Small molecules against multiple targets |
| Novartis | January 2024 | $37.5M, plus funding for some research costs | Up to $1.2B | Small molecules against three targets |
| Novartis, expansion | February 18, 2025 | Same terms as the original deal | Same terms as the original deal | Up to three more research programmes |
| Johnson & Johnson | January 20, 2026 | Not disclosed | Not disclosed | Multi-target research across small molecules, antibodies, peptides and molecular glues |
The two 2024 deals together came to $82.5 million upfront and up to $2.9 billion in milestones. The milestone figures are contingent. See biobucks for why the upfront number is the one to compare. No approved medicine has come from any of the three partnerships.
The Clinical Trial Timeline as Stated
| When | Who | What was said |
|---|---|---|
| 2025 | Demis Hassabis, founder and CEO | AI-designed drugs would be in clinical trials by the end of 2025, as later summarised by Reuters |
| January 20, 2026 | Demis Hassabis, at a World Economic Forum event in Davos | The company expects its first clinical trials by the end of 2026, per Reuters |
| May 12, 2026 | Company press release on the Series B | Says funds will move programmes "toward the clinic". Gives no trial date |
| September 2026 | Sacra company profile | No clinical candidate had been named publicly |
| November 2, 2026 | Max Jaderberg, president, at a Bloomberg event in London | Described the company as in its "first innings", according to The Neuron |
| November 3, 2026 | The Neuron | No Isomorphic candidate had entered human trials and the company had not confirmed any trial start |
A search of ClinicalTrials.gov on November 13, 2026 for studies sponsored by Isomorphic returned no records. A trial run by a partner or under another sponsor name would not appear in that search.
Some websites have reported an Isomorphic drug called ISL-001 in Phase 2. We found no registry record, company statement or established outlet supporting that, and it contradicts the reporting above. A compound called ISM8969 that appears in some articles about Isomorphic belongs to a different company, Insilico Medicine.
Pipeline
The company says it has both partnered programmes and wholly owned ones, and has not named a candidate. R&D World reported 17 active programmes across oncology, immunology and cardiovascular disease in May 2026. We could not confirm that count in a company source. Offices are in London, Cambridge, Massachusetts, and Lausanne.
For comparison with compounds from other AI drug companies that are already in trials, see AI-designed drugs in clinical trials. For how Isomorphic differs from the life-science products of OpenAI and Anthropic, see Claude Science vs GPT-Rosalind vs Isomorphic Labs.
Methodology
Round details come from Isomorphic's May 12, 2026 press release. The 2025 round, the Davos statement and the earlier target come from Reuters, read via Investing.com. Totals come from Sacra and R&D World. The Johnson & Johnson deal is from Isomorphic's announcement, and the 2024 terms from BioSpace. November status is from The Neuron and our own query of the ClinicalTrials.gov API. Status as of November 13, 2026.